Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors

Investigative Ophthalmology and Visual Science

Volumn 39, Issue 8, 1998, Pages 1300-1311

  Giuliano, Michela ^a   Lauricella, Marianna ^a   Vassallo, Erasmo ^a   Carabillò, Maria ^a   Vento, Renza ^a   Tesoriere, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE ORANGE; AMSACRINE; CAMPTOTHECIN; CYCLOHEXIMIDE; DACTINOMYCIN; DNA FRAGMENT; DNA TOPOISOMERASE INHIBITOR; ETHIDIUM BROMIDE; ETOPOSIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN P21; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

APOPTOSIS; ARTICLE; COLORIMETRY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MICROSCOPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RETINOBLASTOMA;

AMSACRINE; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CAMPTOTHECIN; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYCLOHEXIMIDE; DACTINOMYCIN; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETINAL NEOPLASMS; RETINOBLASTOMA; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031802434     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Kyritsis AP, Tsokos M, Triche TJ, Chader GJ. Retinoblastoma origin from a primitive neuroectodermal cell. Nature. 1984;307:471-473.
2. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820-823.
3. Knudson AG. Mutation and human cancer. Adv Cancer Res. 1973; 17:317-352.
4. Horowitz JM, Park SH, Bogenmann E, et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA. 1990;87:2775-2779.
5. Lee EY-HP, Bookstein R, Young L-J, Lin C-J, Rosenfeld MG, Lee W-H. Molecular mechanism of retinoblastoma gene inactivation in retinoblastoma cell line Y79. Proc Natl Acad Sci USA. 1988;85: 6017-6021.
6. Giuliano M, Vento R, Lauricella M, Calvaruso G, Carabillò M, Tesoriere G. Role of insulin-like growth factors in autocrine growth of human retinoblastoma Y79 cells. Eur J Biochem. 1996; 236:523-532.
7. Schwartzman RA, Cidlowski JA. Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocrinol Rev. 1993;14:133-151.
8. Mani S, Ratain MJ. Promising new agents in oncologic treatment. Curr Opin Oncol. 1996;8:525-534.
9. Hsiang Y-W, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase. I. DNA cleavable complexes as a mechanism ot cell killing by camptothecin. Cancer Res. 1989;49: 5077-5082.
10. Kessel D. Effects of camptothecin on RNA synthesis in leukemia L1210 cells. Biochim Biophys Acta. 1971;246:225-232.
11. Bosmann HB. Camptothecin inhibits macromolecular synthesis in mammalian cells but not in isolated mitochondria or E. coli. Biochem Biophys Res Commun. 1970;41:1412-1420.
12. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multi-drug resistance. Mol Pharmacol. 1996;50:1536-1540.
13. Goldwasser F, Bae I, Fornace AJ, Pommier Y. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines. Oncol Res. 1996;8:317-323.
14. Pommier Y, Kohn KW. Topoisomerase II inhibition by antitumor intercalators and demethylepipodophyllotoxins. In: Glazer RI, eds. Developments in Cancer Chemotherapy. Broca Raton, FL: CRC Press; 1989:175-196.
15. Pommier Y, Orr A, Kohn KW, Riou JF. Differential effects of amsacrine and epipodophyllotoxin on topoisomerase II cleavage in the human c-myc protooncogene. Cancer Res. 1992;52:3125-3130.
16. Gromova II, Thomsen B, Razin SV. Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-Myc gene locus in living cells and in high-salt-extracted nuclei. Proc Natl Acad Sei USA. 1995;92:102-106.
17. Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev. 1996;6:12-19.
18. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993; 74:957-967.
19. White E. p53, guardian of Rb. Nature. 1994;371:21-22.
20. Herwig S, Strauss M. The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. Eur J Biochem. 1997;246:581-601.
21. Inomata M, Saijo N, Kawashima K, et al. Induction of apoptosis in cultured retinoblastoma cells by the protein phosphatase inhibitor, okadaic acid. J Cancer Res Clin Oncol. 1995;121:729-738.
22. Kyritsis A, Joseph G, Chader GJ. Effects of butyrate, retinol, and retinoic acid on human Y-79 retinoblastoma cells growing in monolayer cultures. J Natl Cancer Inst. 1984;73:649-654.
23. Conway RM, Madigan MC, Penfold PL, Billson FA. Induction of apoptosis by sodium butyrate in the human Y79 retinoblastoma cell line. Oncol Res. 1995;7:289-297.
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application and cytotoxicity assay. J Immunol Methods. 1983;65:55-63.
25. Jarvis WD, Kolesnick RN, Fornari FA, Traylor RS, Gewirtz DA, Grant S. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci USA. 1994;91:73-77.
26. Vento R, Tesoriere G, Giuliano M, Calvaruso G, Lauricella M, Carabillò M. Synthesis of insulin and its effects in Y79 human retinoblastoma cells. Exp Eye Res. 1994;59:221-229.
27. Leist M, Gartner F, Bohlinger I, Germann PG, Tiegs G, Wendel A. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-α requires transcriptional arrest. J Immunol. 1994;153:1778-1788.
28. Sumantran VN, Ealovoga MW, Nunez G, Clarke MF, Wicha MS. Overexpression of Bcl-xl sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res. 1995;55:2507-2510.
29. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
30. Martin SJ, Lennon SV, Bonham AM, Cotter TG. Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J Immunol. 1990;145: 1859-1867.
31. Orcn M, Prives C. p53: upstream, downstream and off stream. Biochim Biophys Acta. 1996;1288:R13-R19.
32. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose)polymerase by a proteinase with properties like ICE. Nature. 1994;371:346-347.
33. Kroemer C. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 1997;3:614-620.
34. Cosulich SC, Green S, Clarke PR. Bcl-2 regulates activation of apoptotic proteases in a cell-free system. Curr Biol. 1996;6:997-1005.
35. Hansen R, Oren M. p53; from inductive signal to cellular effect. Curr Opin Genet Dev. 1997;7:46-51.
36. Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 1996;10:2438-2451.
37. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
38. Howes KA, Ransom N, Papermaster DS, Lasudry GH, Albert DM, Windle JJ. Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev. 1994;8:1300-1310.
39. Nork TM, Poulsen GL, Millecchia LL, Jantz RG, Nickells RW. p53 regulates apoptosis in human retinoblastoma. Arch Ophthalmol. 1997;115:213-219.
40. Kondo Y, Kondo S, Liu J, Haqqi T, Barnett GH, Barna BP. Involvement of p53 and WAF1/CIP1 in y-irradiation-induced apoptosis of retinoblastoma cells Exp Cell Res. 1997;236:51-56.
41. Wu Y, Huang H, Miner Z, Kulesz-Martin M. Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53. Proc Natl Acad Sci USA. 1997;19:8982-8987.
42. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53 Cell. 1995;83: 237-245.
43. Lutzker SG, Levine AJ. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat Med. 1996:2 804-810:.
44. Sepehrnia B, Paz BI, Dasgupta G, Momand J. Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. J Biol Chem. 1996;271: 15084-15090.
45. Blaydes JP, Gire V, Rowson JM, Wynford-Thomas D. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by MDM-2. Oncogene. 1997;14:1859-1868.
46. Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S, Prives C. Identification od redox/repair protein Ref-1 as a potent activator of p53. Genes Dev. 1997;11:558-570.
47. Knippschild U, Milne D, Campbell L, Meek D. p53 N-terminus-targeted protein kinase activity is stimulated in response to wild type p53 and DNA damage. Oncogene. 1996;13:1387-1393.
48. Knippschild U, Milne DM, Campbell LE, et al. P53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs. Oncogene. 1997;15:1727-1736.
49. Selvakumaran M, Lin H-K, Miyashita T, et al. Immediate early up-regulation of bax expression by p53 but not TGFβ1: a paradigm for distinct apoptotic pathways. Oncogene. 1994;9:1791-1798.
50. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell. 1994;2:329-339.
51. Tsujimoto Y, Croce C. Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA. 1986;83:5214-5218.
52. Farrow SN, Brown R. New members of the Bcl-2 family and their protein partners. Curr Opin Genet Dev. 1996;6:45-49.
53. Jakobson MD. Apoptosis. Bcl-2 related proteins get connected. Curr Biol. 1997;7:R277-R281.
54. Rubin R, Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest. 1995; 73:311-331.
55. Sell C, Baserga R, Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res. 1995;55:303-306.
56. O'Connor R, Kauffmann-Zeh A, Liu Y, et al. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol Cell Biol. 1997;17:427-435.
57. Singleton JR, Dixit VM, Feldman EL. Type I insulin-like growth factor receptor activation regulates apoptotic proteins. J Biol Chem. 1996;271:31791-31794.
58. Doz F, Neuenschwander S, Plantaz D, et al. Etoposide and carboplatin in extraocular retinoblastoma: a study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol. 1995;13:902-909.
59. Pratt CB, Fontanesi J, Chenaille P, et al. Chemotherapy for extraocular retinoblastoma. Pediatr Hematol Oncol. 1994;11:301-309.
60. Zamble DB, Lippard SJ. Cisplatin, and DNA repair in cancer chemotherapy. Trends Biochem Sci. 1995;20:435-439.
61. Blommaert FA, van Dijk-Knijnenburg HC, Dijt FJ, et al. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry. 1995;34:8474-8480.
62. 2-ceramide. Mol Cell Biochem. 1998. In press.